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 FOREWORD 
 
The Trent  Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Purchasing 
Authorities Chief Executives (PACE) and the Trent Development and Evaluation Committee 
(DEC). A public health consultant from a purchasing authority leads on each topic assisted 
by a support team from ScHARR, which provides help including literature searching, health 
economics and modelling. A seminar is led by the public health consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been reviewed by the 
Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
LQWHUYHQWLRQV7KH7UHQW,QVWLWXWH¶V:RUNLQJ*URXSRQ$FXWH3XUFKDVLQJKDVMRLQHGDZLGHU
collaboration, InterDEC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development, The Scottish Health Purchasing Information Centre 
(SHPIC) and The University of Birmingham Department of Public Health and Epidemiology. 
 
 
 
 
 
 
 
Professor R L Akehurst, 
Chairman, Trent Working Group on Acute Purchasing. 
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EXECUTIVE SUMMARY 
 
This Guidance Note for Purchasers examines the evidence for the effectiveness and cost-
effectiveness of alpha interferon in the treatment of chronic myeloid leukaemia (CML). 
 
Chronic Myeloid Leukaemia 
 
CML is a haematological malignancy with peak incidence rate in the late 8th decade of life, 
though typically for cancers, incidence rates rise steadily with increasing age. Prior to the 
use of alpha interferon, no treatment had been shown to alter significantly the course of the 
disease. 
 
Alpha Interferon 
 
Alpha interferon is one of a family of drugs produced by genetic recombinant technology, 
manufacture being by fermentation methods. This technology is intrinsically expensive 
because of the possibility of batch contamination resulting from gene mutation. As a result, 
such drugs are likely to remain expensive even once the research and development costs 
are recouped and the drugs come off patent. 
 
Evidence of Effectiveness 
 
There is very strong evidence of effectiveness in terms of extension of survival, with three  
independent randomised controlled trials (RCTs) showing similar benefit over conventional 
chemotherapy. None of these studies has followed a trial cohort through to death, but ended 
typically after six years. The degree of benefit is more contentious therefore, depending on 
the method used to calculate it; each method having different sources of error. 
 
Cost-effectiveness 
 
The high cost of the drug and need for continuing treatment (as opposed to a course or 
courses of treatment) means that the cost-effectiveness could never be better than £10,000 
per Quality Adjusted Life Year (QALY). Using the data presented from the MRC trial,1 up to 
six years the cost-effectiveness is £75,000/life year gained (LYG) or £84,750/QALY.  
2 
If treatment is restricted to those patients who demonstrate a haematological response by 
six months of treatment, then the cost-effectiveness improves to £53,820/LYG or 
£60,800/QALY. 
 
Implications for the Average Health Authority 
 
Treatment prevalence for a typical district of 500,000 population would be 16 patients, 
costing £160,000 per annum; 11 patients costing £115,000 per annum for the selective 
model treating only haematological responders; 3 patients costing £60,000 per annum for 
the selective model treating only cytogenetic responders. 
 
Conclusions 
 
This is a treatment of proven effectiveness but at very high cost compared to other health 
care activity. Therefore, it must be considered to be a low priority for funding. Options are 
limited, with no practical opportunity to target treatment at a small group with larger benefits. 
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1. INTRODUCTION 
 
1.1 Chronic Myeloid Leukaemia : Incidence and Pathology 
 
The registration rate for England and Wales in 1989 was 1.4/100,000, whilst the average 
annual registration rate in the Trent region for the period 1979 to 1994 was 1.5/100,000. In 
Trent, 64% of registrations were aged <75, (in England and Wales the figure was 55%) 
giving an under 75 average annual incidence for Trent of about 1/100,000 total population. 
 
1.2 Prognosis and Mortality 
 
The disease follows a pattern of a prolonged insidious chronic phase (lasting 3-4 years, 
though the natural history is confused by late presentation), followed by a rapidly 
progressive accelerated phase leading to death within a few months. Survival curves from 
Trent Cancer Registry data are presented in Figure 1.  
 
Only data from 1979 to 1994 have been used, as prior to 1979 the data appear suspect and 
only subsequently stabilise, whilst after 1994 the data are incomplete. 
 
7KHHQWU\FULWHULDIRUWKH05&VWXG\ZHUH³XQGHU\HDUVDQGLQILUVWFKURQLFSKDVH
Patients over 75 were excluded because of the risk of neurotoxicity from IFN-D WKHUDS\´1 
Curves for all patients are given, as well as for those under 75 years of age (the MRC study 
population). Data for those surviving more than one year are also given as the group most 
likely to have presented with chronic myeloid leukaemia (CML) in the chronic phase (cf. 
MRC patients) rather than in the accelerated, terminal phase. 
 
1.3 6FDOHRIWKH3UREOHPLQDµ7\SLFDO'LVWULFW¶ 
 
The age structure of patients in the MRC trial does not match that of the Trent cancer 
registration data (Table 1), and it would appear that there was a substantial exclusion of 
patients aged 60-74. 
 
4 
Figure 1: CML (ICD9:205.1) Deaths in Trent 1979-1994: Length of Survival
0
50
100
0 12 24 36 48 60 72
Excluding first year deaths, <75 years at diagnosis (median survival 34 months)
Excluding first year deaths (median survival 32 months)
All Trent deaths, <75 years at diagnosis (median survival 16 months)
All Trent deaths (median survival 10 months)
 Source: Trent Cancer Registry 
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Table 1: Age Structures of Chronic Myeloid Leukaemia Populations 
 
AGE BAND IN 
YEARS 
<40 40 to 49 50 to 59 60 to 74 <75 75+ 
 
% BY EACH AGE BAND  
Trent 1979-94 9.7 9.0 12.2 33.3 64.2 35.8 
England and Wales 
1989 
10.3 6.8 9.8 28.4 55.3 44.7 
 
% BY EACH AGE BAND FOR AGES <75 YEARS 
Trent 1979-94 15.1 14.0 19.0 51.9   
England and Wales  
1989 
18.7 12.4 17.7 51.3   
MRC trial 24.9 20.8 27.8 26.6   
 
% BY EACH AGE BAND FOR AGES <60 YEARS 
Trent 1979-94 31.5 29.1 39.5    
England and Wales  
1989 
38.3 25.4 36.3    
MRC trial 33.9 28.3 37.8    
 
 
 
Adjustments to match the MRC structure and thus predict likely treatment use would 
suggest annual incidence at 0.63/100,000 and, with a median survival at five years, a 
treatment prevalence of  3.2/100,000 or 16 patients for the average district of 500,000 
population.  
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2. USE OF ALPHA INTERFERON IN THE MANAGEMENT OF CHRONIC                      
 MYELOID LEUKAEMIA : SUMMARY OF EVIDENCE OF EFFECTIVENESS 
 
The treatment to be considered is alpha interferon, a protein produced naturally by the body, 
which acts as an inter-cellular messenger affecting cell function in the immune system. 
 
Alpha interferon is one of a family of drugs produced by genetic recombinant technology, 
manufacture being by fermentation methods. This technology is intrinsically expensive 
because of batch contamination resulting from gene mutation. As  a result, such drugs are 
likely to remain expensive even once the R&D costs are recouped and the drugs come off 
patent. 
 
Three products are currently licensed for the treatment of CML: Intron A (Schering-Plough); 
Roferon-A (Roche); Wellferon (Wellcome). Treatment protocols recommended in each data 
sheet are quite different. 
 
Treatment was continuous in the trials and there are, as yet, no recommendations on 
duration of treatment. 
 
2.1 Conclusion on Direction of Evidence and its Quality 
 
There were three randomised controlled trials (RCTs)1,2,3 of alpha interferon reported in the 
literature in 1994 and 1995; the results of studies started in the 1980s. A fourth RCT (alpha 
interferon vs busulphan) was published in 19954 but the data are curtailed much earlier than 
the other three studies (median follow-up just 50 months) and survival is given as predicted 
five year survival rates, rather than median survival time. The outcome comfirms those in 
the other trials but the data are not presented in such a way as to allow detailed comparison. 
 
Comparisons of the three studies 
A tool for the assessment of severity at presentation, the Sokal risk score, has been 
developed, and the data presented in the three studies allow comparison of the casemix  at 
entrance to the three studies; however, the dose of alpha interferon given in these trials 
differed (Table 2). 
Table 2: Casemix and Dosage in Trials 
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 ITALIAN STUDY
2
 GERMAN STUDY
3
 MRC STUDY
1
 
Proportion of 
Patients in High 
Sokal Risk Group 
24% 36% 42% 
 
Average Dose of 
Alpha Interferon 
7 MIU 3.5 MIU 3.2 MIU 
 
Each study used standard chemotherapy treatment, hydroxyurea or busulphan, for the 
control group, and the proportion of patients in each Sokal risk group was essentially similar 
in the alpha interferon arm and control arm within each of three trials, but not between them. 
All three studies were well-conducted RCTs showing statistically significant benefit for 
patients receiving alpha interferon regimens, with the exception of the interferon vs 
hydroxyurea arm of the German trial. The marginal benefit of alpha interferon over standard 
chemotherapy, as measured by median survival, was 20 months in the MRC and Italian 
trials and in the busulphan controlled part of the German trial (combined data from the two 
arms were not presented in the paper; only the busulphan arm is considered in this 
Guidance Note, the hydroxyurea arm failing to demonstrate significant differences). The 
severity of the disease as measured by the Sokal risk score was shown to be a strong 
predictor of survival in the chemotherapy groups and alpha interferon groups (Figure 2), 
which, in itself, might explain the longer survival in both arms of the Italian study in which the 
percentage of patients in the high Sokal group was half that of the MRC study. 
 
When a crude survival graph is generated from the data in the 1924 JAMA paper,
5
 the curve 
follows closely the chemotherapy curve for the MRC trial up until the third year, but is very 
different from the Italian chemotherapy curve. Again, this may be explained by differences in 
the casemix of severity in the various groups studied. Survival curves are shown in Figure 3. 
 
8 
2.2 Evidence Concerning the Use of Smaller Doses 
 
A very small US study6 on 41 patients used doses averaging half the weekly dose of the 
MRC trial, but there is no information in the paper on casemix in the form of a Sokal score; 
therefore, comparisons are not possible and the claim that the outcome was equivalent to 
higher doses cannot be supported. On the other hand, a review points to the trend for higher 
rates of cytogenetic response with higher doses.7 
 
Two MRC dose ranging trials are currently under way (CML IV and V). These trials started 
in 1996 and 1995 respectively, therefore, the results cannot be expected for some time. 
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Figure 2: Differences Between the Three Studies in Sokal Risks
and Survival Rates
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3. COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
3.1 Trent Analysis 
  
3.1.1 Survival Benefit 
 
Marginal survival advantage has been calculated as the area between the survival curves 
for the alpha interferon and control groups. The MRC trial data have been used as they give 
the UK experience and also appear to have the most favourable outcome. A theoretical 
cohort of 100 patients in each arm of the trial was used to generate the survival curves and 
marginal survival advantage. 
 
Although this is technically the most accurate method to calculate total survival for the 
cohorts, it is not without problems. The data are curtailed at six years and the tails may be 
important, especially if any patients are cured. A Cox regression model could be used to 
simulate a tail, generating survival curves based on survival ratios averaged across the six 
years, thus avoiding the problems of random variations in any arbitrary single point 
measure. However, this assumes some constancy of survival ratios, whilst the reality may 
be one of systematic changes in survival ratios. Such situations are typically seen in trials 
with the survival curves of cases and controls first diverging then converging again, if only 
because of deaths from other diseases, especially in the elderly. 
 
Cumulative survival advantage for an alpha interferon treatment cohort is presented in 
Figure 4. 
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Figure 4: Cumulative Survival Advantage for Alpha Interferon Cohort 
of 100
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3.1.2 Costs 
 
The major part of the cost of treatment is that of alpha inteferon, whilst the standard 
chemotherapy costs are very small at between £100 and £200 and have been ignored for 
this analysis. Using the MRC dosages, theoretical costs of alpha interferon would be £6,666; 
one Trust has reported actual costs to average about £10,000 per annum, which is an 
ongoing annual cost. This actual figure of  £10,000 per annum has been used in the 
analysis presented in this Guidance Note. 
 
Again, the survival curve for alpha interferon has been used to generate cumulative 
treatment costs; this gives the actual costs allowing for the reducing size of the cohort being 
treated with time. Cumulative costs are presented in Figure 5. 
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Figure 5: Cumulative Costs of Alpha Interferon  for Cohort of 100
0
500,000
1,000,00
1,500,00
2,000,000
2,500,000
3,000,000
3,500,000
4,000,000
4,500,000
1 2 3 4 5 6
Duration of Treatment (years)
       Costs £s
 
 
3.1.3 Cost-effectiveness  
 
Cost-effectiveness has been calculated as marginal costs per life year gained (LYG)  
(Figure 6). The Wessex DEC report8 assumed a quality of life rating of 0.885 on alpha 
interferon (similar to the 0.9 used in other economic analyses9) or standard treatment which 
would give a cost per Quality Adjusted Life Year (QALY) 13% higher than the cost per LYG. 
 
This analysis shows that the cost-effectiveness is £75,000 per life year gained or £84,750 
per QALY. 
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Figure 6:       Economic Analysis of Alpha Interferon in the Treatment of Chronic   
Myeloid Leukaemia Assuming Annual Treatment Cost of £10,000
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3.1.4 Treatment Sub-groups 
 
The MRC trial identified a large sub-group of patients with a slightly better outcome. Those 
SDWLHQWV ZLWK DQ µ$ W\SH¶ KDHPDWRORJLFDO UHVSRQVH ZLWKLQ WKH ILUVW VL[ PRQWKV RI WUHDWPHQW
with alpha interferon, about 70% of the cohort, had a better relative prognosis. A cost-
benefit analysis of this sub-group is also presented, based on treatment for all to six months, 
then selecting responders only for long-term treatment. 
 
Despite the claims that the Sokal score may predict marginal benefit on alpha interferon,7 
with high risk patients fairing poorly, there is no evidence in these trials to support that claim. 
The MRC trial has the largest proportion of high risk patients, yet the marginal benefit is at 
least as good as, if not better than, the Italian and German trials. 
 
It has been suggested that complete cytogenetic responders, that is, those patients showing 
bcr/abl negativity on qualitative polymerase chain reaction (PCR)a or Southern blot test, may 
have had their Philadelphia chromosome anomalies eradicated and, thus, actually be 
cured,7 but more intensive quantitative examination showed residual disease still to be 
present in such patients.10 Furthermore, the number of such cytogenetic responders 
increases with duration of treatment, with major and complete response taking the longest.3 
A proposed protocol7 suggests that only patients showing any cytogenetic response at six 
months, or Philadelphia chromosome count < 50% at 12 months, should continue treatment. 
With a median time to mild cytogenetic response in the MRC trial3 at 32 weeks (range 4 -
108) and only 22% of patients showing any cytogenetic response during the trial, this would 
certainly limit the numbers on treatment. However, it is not clear from the available literature 
whether this selected group would include or exclude those with the best cytogenetic 
response (major or complete response, 11%), i.e. the group of patients showing the best 
survival. The data presented in the papers do not permit a cytogenetic responder sub-group 
health economic analysis; although the data do point to a better cost-effectiveness profile, it 
cannot be quantified. The best that could be achieved would be £10,000 per QALY for those 
thus selected, but adjusted to £20,000 - £30,000 per QALY to allow for those on trial of 
treatment achieving no health gain. 
 
                                            
a
 A test on the cellular DNA that detects defects. 
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3.1.5 Sensitivity Analysis 
 
There are a number of variables which could have an impact on the cost-effectiveness 
calculations: 
a the accuracy of the method of estimating true survival benefit; 
b the dose of alpha interferon (see 2.2 above); 
c wasted doses of alpha interferon;  
d quality of life estimates. 
Using the best possible outcome (increase in median survival of 20 months), theoretical 
drug usage rather than actual, and a quality of life on alpha interferon of 1.0, then the most 
favourable cost-effectiveness estimate is £20,170 per QALY (see Table 3 below). 
 
 
 
Figure 7: Survival Curve for all 130 Patients in 1924 JAMA paper
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3.2 Wessex DEC Analysis8 
 
3.2.1 Survival Benefits 
 
The Wessex team has chosen to create an historical control group for the purposes of 
analysing benefits for alpha interferon and standard chemotherapy (the latter despite 
assertions that standard chemotherapy does not alter disease progression). This generates 
survival benefits for alpha interferon of 36 and 21 months for the Italian and MRC trials 
respectively. The use of historical controls is well known to be fraught with problems. In this 
case, a major problem can be clearly illustrated. The source of the historical data is a 1920s 
trial of radiotherapy published in the JAMA.5 The patients are clearly a selected group when 
compared to those on the Trent Cancer Registry, with survival curves being markedly 
GLIIHUHQW2QO\ZKHQ7UHQW¶VILUVW\HDUGHDWKVDUHH[FOXGHGGRHVWKH7UHQWPHGLDQVXUYLYDO
of 33 months approach the JAMA figure of 36 months (Figure 7). 
 
As has been shown earlier, the Sokal risk score is a potent predictor of survival. The 
proportion of high risk patients varies between the three trials with concomitant variation in 
survival. As the Sokal profile of the historical controls is unknown, comparisons between 
outcomes in any of the three trials and the historical controls is inappropriate. 
 
At the end of the Wessex paper, passing reference is made to marginal benefit over 
conventional chemotherapy but, again, comparisons within trials are not made and there is 
no presentation of marginal cost-utility analysis. Marginal benefits within trials are very 
similar; for each trial there is a 20 months improvement in median survival: MRC 61 vs 41; 
Italian 72 vs 52; German 66 vs 46 (busulphan arm). 
 
The use of median survival as the outcome measure for comparison is also open to 
question. Median survival is an arbitrary uni-dimensional measure, established by 
convention (as is five year survival). It is a measure of the average which may differ 
FRQVLGHUDEO\ IURP WKH PHDQ ,W ZRXOG EH DQ DFFXUDWH PHDVXUH LI VXUYLYDO µFXUYHV¶ ZHUH
straight lines, but it is an inappropriate measure for a complex curve. In particular, in 
assessing the difference between survival of two cohorts, it fails to take into account the 
possibility (indeed probability) that the curves eventually reconverge. 
 
3.2.2 Costs 
 
18 
There are two additional sources of error, although they counter each other. Firstly, Wessex  
uses theoretical costs based on average dose to give £6,613 per annum for the MRC trial as 
opposed to the reported actual cost of £10,000 per annum used here. The Wessex DEC 
GRHVQRWH WKLVKRZHYHU ³7KHFRVWXWLOLW\  GRHVQRW WDNHDFFRXQWRI WKH FRVW RIXQXVHG
LQWHUIHURQLQWKHRSHQHGYLDO´ 
 
The second results from the use again of median survival, this time for the calculation of 
lifetime costs. If a cost of £10,000 per annum is applied to the Wessex data then lifetime 
costs become £50,833, whereas using the survival curve gives costs (up to six years) of 
£41,163.  
 
3.2.3 Cost-effectiveness Analysis 
 
The Wessex analysis of cost-utility gives a cost per QALY of £26,020 and £12,080 for the 
Italian and MRC trials respectively. If marginal benefits within trials and adjusted costs at 
£10,000 per annum are used, then the cost-utility calculations using marginal median 
survivals from the MRC trial are much closer to those presented above (Section 3.1.3). 
 
3.3 Annals of Internal Medicine Analysis9 
 
This analysis is based on complex modelling techniques using decision trees and 
probabilities to generate both costs and benefits for a 50 year old and appears to be based 
on USA practice, which is much more aggressive (using intensive in-patient treatment) 
during the accelerated phase and blast crises than is practice in the UK. 
 
3.3.1 Survival Benefits 
 
The model generates median survivals of 69 months on alpha interferon and 58 months on 
hydroxyurea, but life expectancies (mean survival) of 91 and 73 months respectively; the 
difference reported being due to the long survival tails seen in CML. The median survival  
benefit is less than the 20 months actually seen in the three RCTs (though, of course, the 
German hydroxyurea arm showed no significant benefit), whilst life expectancy benefit is 
closer at 18 months. The analysis uses mean survival as its benefit which is equivalent to 
using the area under the survival curve. It is not possible to generate true mean survivals 
from the MRC and Italian data as they are curtailed at six years, but figures up to six years 
are presented in Table 4. 
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The data from the Trent Cancer Registry (Figure 1) for those under 75 years of age and 
surviving longer than one year (i.e. an approximation to the study group) do not give the 
large difference between median and mean seen in the Annals of Internal Medicine model. 
 
Patients on alpha interferon were ascribed a Quality of Life (QOL) score of 0.9 as against 
1.0 for those on hydroxyurea. Wessex used 0.885 for both treatment groups, the figure also 
used to adjust the years of life in the Trent analysis presented in this Guidance Note. 
 
3.3.2 Costs 
 
Costs on the other hand have been generated in a highly sophisticated way more closely 
resembling the survival curve method. However, whilst the lifetime cost for the alpha 
interferon arm does not seem greatly different from the UK cost at $118,000 (about 
£74,000), the hydroxyurea arm was prodigiously costly at $93,000 (about £58,000), 
reflecting the use of in-patient treatments. 
 
3.3.3 Cost-effectiveness Analysis 
 
The (discounted) marginal cost-effectiveness for the 50 year old was $26,500 (about 
£16,600) per LYG, and cost/utility $34,800 (about £21,700) per QALY. These figures are 
sensitive to the cost of alpha interferon, the age of the patient and quality of life measures; 
however, in terms of comparison with the other two analyses above, it is the reported cost of 
hydroxyurea $93,000 (about £58,000) that is a key feature. If that cost better reflected the 
costs of hydroxyurea suggested in the UK, the marginal costs and, thus, the cost-
effectiveness, would be four times higher and, therefore, greater than our Trent estimate. 
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Table 3: Comparisons Between Wessex,  Trent  and Best Outcome Analyses 
 
Analysis Annual 
Costs  
 
 
£ 
Lifetime Costs  
 
£  
 
(Not Discounted) 
Benefit Over 
Historical 
Controls:  
 
Survived 
Months 
Benefit Over Italian 
Hydroxyurea 
Controls:  
 
Survived Months 
In-Trial 
Marginal 
Benefit:  
 
Survived 
Months 
QOL Adjusted 
Benefit:  
 
 
Years 
Cost/QALY  
 
 
 
£ 
Wessex  
MRC 
 6,613  33,616 25    2.5  13,450 
Wessex  
MRC 
 6,613  33,616  9   0.7  48,020 
Wessex  
MRC 
 10,000  50,833     20  1.48  34,460 
Trent  
MRC 
 10,000  41,163    6.6  0.49  84,750 
Trent  
MRC 
 6,613  33,616    6.6  0.49  69,210 
Most 
favourable 
 6,613  33,616    20  1.67  20,170 
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Table 4: Comparisons Between Median and Mean Survivals 
 
Data Source Median Survival: 
Months 
Mean Survival: 
Months 
Difference Between Mean 
and Median:  
Months 
Annals of Internal Medicine 
Analysis: Alpha Interferon 
69 91 22 
Annals of Internal Medicine 
Analysis: Hydroxyurea 
58 73 15 
Trent Region: all 10 20 10 
Trent Region: aged <75 16 25 9 
Trent Region: all surviving      
> 1 year 
32 39 7 
Trent Region: aged <75 
surviving >1 year 
34 41 7 
Trent Region: aged <75 
surviving >1 year curtailed at 
6 years 
30 34 4 
MRC Trial to 6 years: Alpha 
Interferon 
61 49* -12 
MRC Trial to 6 Years: 
Chemotherapy 
41 43* 2 
Italian Trial to 6 years: Alpha 
Interferon 
72 56* 
 
-16 
Italian Trial to 6 Years: 
Chemotherapy 
52 50* -2 
* calculated from area under survival curve. 
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Figure 8:                  Economic Analysis of Alpha Interferon in the                                           
Treatment of Chronic Myeloid Leukaemia Assuming Annual Treatment Cost of £10,000
1,138,125
1,217,141
573,933
207,357
128,715
92,447 71,662 5
0
200,000
400,000
600,000
800,000
1,000,000
1,200,000
1,400,000
1 2 3 4 5 6 7 8
Years of Treatment
Co
st
 
£s
Marginal cost/survival benefit of alpha interferon over standard chemotherapy: Italian Trial
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3.4 Conclusions 
 
The shape of the survival curve is crucial in determining the relationship between the 
median and the mean. The median survival, a point measure, is suspect as a measure of 
the true average survival of a cohort that would permit an accurate estimate of benefit. The 
mean is dependent on the nature of the tail occurring after the end of the trial. The shape of 
that tail is dependent on both the effectiveness of the drug (a large effect would increase the 
mean with time) and the age of the cohort (an elderly cohort would see large numbers of 
non-CML deaths in the tail, reducing the mean with time). The Italian trial shows the most 
favourable survival curves, still diverging in year six, but in year six the number necessary to 
treat is three (four in the MRC trial), giving a cost-effectiveness for that year of £30,000. It is 
unlikely, therefore, that even a favourable tail would have much impact on the overall cost-
effectiveness profile. Figure 6 gives an impression of the changes in cost-effectiveness with 
time for the MRC study, illustrating the tendency for the curve to flatten out; Figure 8 shows 
the same analysis for the Italian data, projected to year eight. 
 
However, the mean at six years as calculated in the Trent analysis, is the most accurate 
calculation of average survival using the data available, rather than attempting 
extrapolations (a process that is not recommended).10 
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4. OPTIONS FOR PURCHASERS AND PROVIDERS 
 
 
Option 1 Do not fund from mainstream NHS funds as it is not a cost-effective 
treatment. Await further evidence from MRC dose ranging trials. 
 
Option 2 Fund on the basis of selection of haematology responders by six months. 
Supported by the research; clinically appropriate targeting of scarce 
resource. Total costs are less and cost-effectiveness improved, though still 
very poor. 
 
Option 3 Treat only cytological responders (any at six months or Ph chromosome 
count <50% at 12 months). This is likely to be the most cost-effective option; 
though unquantifiable, figures are unlikely to fall below £20,000/QALY 
because of the large numbers of patients initially on trial of treatment for 
whom there will be no health gain. 
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5. DISCUSSION AND CONCLUSIONS 
 
5.1 Technical Issues 
 
Questions can be raised about methodologies, especially as they have such large effects on 
the analyses. However, it is considered that the survival curve method offers the most 
DFFXUDWH HVWLPDWH RI DYHUDJH VXUYLYDO WKRXJK VHQVLWLYH WR WKH SRVW WULDO µWDLO¶ ,W ZDV DOVR
agreed that in-trial, marginal benefit must be used as the benefit outcome to be measured. 
 
5.2 Lower Dose Alternatives 
 
A USA study indicates that much smaller doses of alpha interferon can be used without 
reducing benefits. These data are mentioned in paragraph 3.3 above. The MRC dose 
ranging studies will confirm or refute the preliminary results of that trial. 
 
5.3 Possibility of Cure 
 
It can be suggested that a small sub-group of patients has cytogenetic responses indicative 
of cure, a claim mirrored in the literature.7 However, this is apparently refuted by more 
detailed analysis.11 
 
5.4 Meta-analysis 
 
A meta-analysis of the three trials should improve the quality of the information and possibly 
identify sub-groups which might derive greater benefit. In particular, the effect of Sokal 
scores on outcomes of treatment as well as the prognostic significance of the 
haematological and/or cytogenetic responses needs to be addressed given the conflicting 
information in the literature. 
 
A comparative analysis of the Italian and German trials has been published in the form of a 
letter.12 It seeks to compare the data for the two trials by retrospectively applying uniform 
entry criteria. It is not, however, a meta-analysis and does not answer any of the questions 
raised here. 
 
5.5 Paradoxical Response to Quality Research 
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There appears to be a paradox in that good quality research, which generates data of 
sufficient detail to permit health economic analysis, would be penalised by revealing the true 
costs, whilst poor quality research, or none at all, might deny that analysis and permit poor 
medicine to become normal practice. Nevertheless, this in itself is not a reason to accept 
new cost-ineffective treatments, nor to cease quality research. The role of research is to test 
treatments not prove them. 
 
This is of particular concern for haematologists, as almost uniquely in medical practice, the 
vast majority of their cancer related work is driven by such high quality research. 
 
5.6 Responsibilities of the MRC 
 
Alpha interferon is already used routinely by a number of providers. This is partly the result 
of communications from the MRC informing collaborators of early results, the curtailment of 
the study, and a statement to the effect that it would be unethical to continue the trial and 
deny patients alpha interferon. Clinicians felt that they would be held negligent if they 
subsequently denied alpha interferon to their patients. 
 
In terms of the ethics of the clinical trial as established, the MRC response is sound. In a 
resource constrained environment the ethics are not so clear cut, as alpha interferon 
therapy must be set against other calls on limited resources. In this environment, great care 
is required by those making statements with regard to the ethics around provision of any 
specific treatment. 
 
Broader issues are also raised about the end-points of trials and the questions to be 
answered. Trials designed to answer simple effectiveness questions may fail to provide 
sufficient data necessary for the difficult and complex process of priority setting. 
 
5.7 Comparison with Bone Marrow Transplantation 
 
Bone Marrow Transplantation is also high cost and used in the treatment of CML. A 
comparative cost-effectiveness analysis of these alteratives would be of value. However, it is 
beyond the scope of this report and the need for a RCT to compare these alternatives is 
highlighted elsewhere.9 
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6. USE OF ALPHA INTERFERON IN THE MANAGEMENT OF CHRONIC MYELOID LEUKAEMIA : SUMMARY MATRIX 
 
PATIENT GROUP PATIENT CRITERIA 
(GUIDELINES NOT 
PROTOCOLS) 
ESTIMATED FUTURE 
ACTIVITY 
(treatment prevalence) 
OPPORTUNITY 
FOR COST 
SAVING 
AUDIT POINTS EFFECTS THAT COULD 
BE EXPECTED IN 
RELATION TO STARTING 
POINT 
COST-EFFECTIVENESS 
(after up to 6 years of 
treatment) 
CML patients 
under 75 years. 
 
As per MRC trial entry 
criteria. 
16 per annum 
(3.2/100,000) 
NONE Treatment criteria as 
for MRC trial. Side- 
effects and drop out 
rates. 
Average improvement in 
survival of 6.6 months   
(49 vs 43). 
£75,000/YoL 
£84,750/QALY. 
CML patients 
under 75 years: 
haematological 
responders. 
As per MRC trial entry 
criteria: continued 
treatment only of those 
with haematological 
response by 6 months. 
11 per annum  
(2.2/100,000) 
NONE Treatment criteria as 
for MRC trial plus 
response status. Side- 
effects and drop out 
rates. 
Average improvement in 
survival of 10.4 months   
(53 vs 43). 
£53,820/YoL 
£60,800/QALY. 
CML patients 
under 75 years 
showing 
cytogenetic 
response by 12 
months. 
As per MRC trial entry 
criteria: continued 
treatment only of those 
with any cytogenetic 
response by 6 months or 
Ph count <50% by 12 
months. 
Approx 3* per annum 
plus 3** patients per 
annum on trial of 
treatment 
(0.6/100,000 plus 
0.6/100,00). 
NONE Treatment criteria as 
for MRC trial plus 
cytogenetic response 
status. Side-effects 
and drop out rates. 
UNKNOWN but better than 
either of above. 
UNKNOWN but better 
than either of above. 
  
 Numbers are for an average District of 500,000 population 
 * assumes a median survival much greater at  8 years and 12.5% of patients showing cytogenetic response 
 ** MRC equivalent entry criteria giving annual incidence of 0.63/100,000 (see 1.3 above) 
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